Regulatory debt in medical device development
I think you have heard the word “Technical debt”. It is “a qualitative description of the cost to maintain a system that is attributable to choosing an expedient solution for its development.” The term technical debt was coined by Ward Cunningham in 1992 but after that it has been revised, with the main highlight being that undocumented technical debt is no longer a shortcut, but a liability.
The far less attention is paid to its quieter cousin regulatory debt.
Regulatory debt does this sound familiar?
Regulatory debt accumulates when, during medical device development, conscious or unconscious compromises are made at the expense of regulatory requirements such as “We’ll document this later,” “We’ll consider this later,” “The regulatory body will only ask about this further down the line,” “It’s just a plan,” or “We’ll handle the QMS later; it’s just a certificate on the wall.”
At its core, regulatory debt often reflects something deeper than missing documents. It is a situation where a regulatory-driven way of working has never truly become part of the company culture. You can create procedures and issue instructions, but culture always overrides process.
And as long as nothing seems to break and everything appears to move smoothly forward, this debt remains invisible which is exactly what makes it so deceptive. It only reveals itself at the worst possible moment, when it suddenly starts to cost both time and money.
What regulatory debt actually is?
Regulatory debt is not a single missing document. It is a gradually accumulated collection of small shortcuts that together form a major risk.
Typical examples include acceptance criteria written vaguely (e.g. “clinically acceptable”), test reports or even test plans not clearly linked to the intended use, retrospective Verification and Validation planning, and poorly connected risk management and V&V activities. Requirements are defined retrospectively, with design and development not truly planned: no milestones, no reviews, no checkpoints. These are just examples, yet even these alone can create a substantial barrier and ultimately jeopardize the approval of an otherwise excellent idea.
On paper, everything may look “fine.” But a reviewer does not read documents in isolation; they assess the entire story. The goal is not to satisfy an auditor, but to demonstrate control, consistency, and patient safety.
Why regulatory debt does not hurt immediately
Regulatory debt does not trigger an error message. There is no crash. No red warning triangle to warn you. And that is exactly why it is so easy to take on.
More often than not, everything appears to be progressing as planned: product development moves forward, pilot studies look promising, investors nod approvingly, and timelines seem firmly under control. Everything looks great, even if the cracks are already there.
And this is where the most dangerous thought emerges: “We can always fix the regulatory side later” “We can document this later”.
The moment the debt comes due
Regulatory debt always comes due at the worst possible moment: right before a regulatory submission, during an evaluation or investor review, when clinical performance data proves insufficient, or when a reviewer asks for justifications that were never documented.
Suddenly, it becomes clear that tests need to be repeated, the patient population is not representative, acceptance criteria cannot be justified retrospectively, equivalence claims no longer meet regulatory requirements, critical tests are missing, and the intended use claims cannot be adequately supported by evidence.
At this point, timelines no longer slip by weeks, but by months or even years. And the amount of wasted money becomes impossible to estimate. In some cases, the device may even make it to the market.
However, unresolved regulatory debt does not disappear at approval and that is where the real danger lies. A company may believe that “we made it; everything worked out without all that documentation.” Instead, it often resurfaces post-market, when real-world use exposes gaps in performance, safety, or clinical justification. At that stage, corrective actions become far more complex and costly, with potential consequences for patient safety, company credibility, and long-term viability.
Why regulatory debt is especially dangerous for startups
For startups in medical device development, regulatory debt is a particularly toxic combination. Cash burns faster than in large organizations, time pressure is constant, and trust with investors and partners is still fragile.
Worst of all, regulatory debt cannot be paid off quickly it cannot simply be “fixed in a sprint.”
How to prevent regulatory debt in medical device development
The good news? Regulatory debt is not inevitable. But avoiding it requires resources and a conscious shift in mindset.
It can be avoided by treating regulation as a strategic part of product development, rather than a checklist applied after the fact. Of course, this requires a certain mindset: an acceptance that regulatory work takes time, but that this investment pays for itself many times over.
Regulation helps define what is worth developing not just how to document what has already been done.
Acceptance criteria should be justified early, because if a criterion cannot be justified today, it will not be defensible later. Clinical performance must be explicitly tied to the intended use; a simple “test passed” is meaningless without a clear explanation of its clinical relevance. And finally, every decision should be documented not just the results because reviewers are looking for the reasoning behind the outcome, not the outcome alone.
Documenting decisions also helps surface potential risks early, allowing them to be identified, assessed, and addressed in time.
Final thoughts
Regulatory debt rarely appears on a roadmap or in a burn-rate spreadsheet.
Instead, it surfaces later as regulatory body questions, delayed market entry or when device is already on the market.
That is why a startup that addresses regulation early is not slow. It is strategically fast.
If this resonates, Nometech helps startups identify and reduce regulatory debt before it comes due at the worst possible moment. Contact us and let’s get your regulatory debt under control or, if you’re still at an early stage, make sure it never builds up in the first place.